Additional prospective data assessing the effect of anti-PD-1 immunotherapy in gynecologic malignancies with dMMR is needed in order to confirm which gynecologic cancer types respond to this treatment and at which point in treatment this immunotherapy is most effective. Here, PDCD1 is linked to female reproductive organ cancer.